SCHEMBL8073093

SCHEMBL8073093

COC(=O)[C@H](Cc1ccccc1)NC(=O)C(CC(C)C)NC(=O)OC(C)(C)C

nearest known ligand 0.68

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
REN P00797 5/20 0.68
KLK5 Q9Y337 1/20 0.61
PSEN1 P49768 6/20 0.60
PSEN2 P49810 6/20 0.60
APH1B Q8WW43 6/20 0.60
NCSTN Q92542 6/20 0.60
APH1A Q96BI3 6/20 0.60
PSENEN Q9NZ42 6/20 0.60
CAPN1 P07384 1/20 0.60
CTSS P25774 2/20 0.58
CTSL P07711 1/20 0.58
CTSB P07858 1/20 0.58
CTSK P43235 1/20 0.58
ALDH1A1 P00352 1/20 0.58
THRB P10828 1/20 0.58
CYP2C9 P11712 1/20 0.58
CYP2C19 P33261 1/20 0.58
HSD17B10 Q99714 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28376535 1.00 REN (0.68) RENKLK5PSEN1PSEN2APH1B
SCHEMBL30789039 1.00 REN (0.68) RENKLK5PSEN1PSEN2APH1B
SCHEMBL18171935 1.00 REN (0.68) RENKLK5PSEN1PSEN2APH1B
SCHEMBL7319373 1.00 REN (0.68) RENKLK5PSEN1PSEN2APH1B
SCHEMBL23106755 0.95 REN (0.68) RENKLK5PSEN1PSEN2APH1B
SCHEMBL18229265 0.95 REN (0.68) RENKLK5PSEN1PSEN2APH1B
SCHEMBL22962098 0.95 REN (0.68) RENKLK5PSEN1PSEN2APH1B
SCHEMBL6857159 0.95 REN (0.68) RENKLK5PSEN1PSEN2APH1B
SCHEMBL1913543 0.95 REN (0.68) RENKLK5PSEN1PSEN2APH1B
SCHEMBL8080979 0.94 REN (0.62) RENKLK5PSEN1PSEN2APH1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3297678-B1 AN IMPROVED PROCESSES FOR THE PREPARATION OF CARFILZOMIB OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF LAURUS LABS LTD (IN) 2021-07-07 EP disclosed
US-10329325-B2 Process for the preparation of (S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxo-pentan-2-yl) amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido) pentanamide BIOPHORE INDIA PHARMACEUTICALS PVT. LTD (IN) 2019-06-25 US disclosed
US-20180002377-A1 A PROCESS FOR PURIFICATION OF CARFILZOMIB FRESENIUS KABI ONCOLOGY LIMITED (IN) 2018-01-04 US disclosed
US-20170298093-A1 Process for the Preparation of (S)-4-Methyl-N-((S)-1-(((S)-4-Methyl-1-((R)-2-Methyloxiran-2-YL)-1-OXO Pentan-2-YL) Amino)-1-OXO-3-Phenylpropan-2-YL)-2-((S)-2-(2-Morpholinoacetamido)-4-Phenylbutanamido) Pentanamide BIOPHORE INDIA PHARMACEUTICALS PVT. LTD (IN) 2017-10-19 US disclosed
WO-2016185450-A1 AN IMPROVED PROCESSES FOR THE PREPARATION OF CARFILZOMIB OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF LAURUS LABS PRIVATE LIMITED (IN) 2016-11-24 WO disclosed
WO-2009045497-A1 CRYSTALLINE PEPTIDE EPOXY KETONE PROTEASE INHIBITORS AND THE SYNTHESIS OF AMINO ACID KETO-EPOXIDES PROTEOLIX, INC. (US) 2009-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180002377-A1 A PROCESS FOR PURIFICATION OF CARFILZOMIB GBA1, PSMB5, GBA2 REN 136/4885KLK5 1851/4885PSEN1 4352/4885
US-20170298093-A1 Process for the Preparation of (S)-4-Methyl-N-((S)-1-(((S)-4-Methyl-1-((R)-2-Methyloxiran-2-YL)-1-OXO Pentan-2-YL) Amino)-1-OXO-3-Phenylpropan-2-YL)-2-((S)-2-(2-Morpholinoacetamido)-4-Phenylbutanamido) Pentanamide PSMA1, PSMA2, PSMA6 REN 139/4885KLK5 3233/4885PSEN1 877/4885
US-10329325-B2 Process for the preparation of (S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxo-pentan-2-yl) amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido) pentanamide PSMA1, PSMA2, PSMA3 REN 129/4885KLK5 3279/4885PSEN1 992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.